	1 10-1	IRANSMITTAL LETTER								Case No. 10466/69				
		Serial No.		Filing	Filing Date			Examiner To be assigned			Group Art Unit 1645			
	-	09/902,90 Inventor(s		July 1	July 10, 2001 To be assigned						1040			
(P	E ve	Ashkenaz	zietal.											
S		ିଆରିକ of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME												
HAL	3 0 2007	TO THE COMMISSIONER FOR PATENTS												
) his		W.	Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); paper copy of Sequence Listing; copy of Sequence in computer readable form; Notice to File Corrected Papers; Submissions of Formal Drawings; One Hundred & Twenty-Four											
TENT	& TRADE	Listing in (124) She	computer readal eets of Formal Dr	le form: Not	ice to FIIe Correct	ed Papers; Sub	miss	ions of Formal	Drawing	ıs; One H	undred & Twe	nty-Four		
			Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.											
		× 🖺 🔻	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.											
			Petition for amonth extension of time.											
	Marie William William Marie Ma		No additional fee is required. The fee has been calculated as shown below: Other Than											
		, 1												
								Small	Entity		Other Small			
			Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Ädd'I Fee	or	Rate	Add'I Fee		
		Total		Minus				x \$9=			x \$18=			
		Indep.		Minus				x 42=			x \$84=			
	TOTAL STORE STORE SECONDARY STORE SECONDARY SE	First Pre	sentation of Multi	ple Dep. Clai	aim			+\$140=			+ \$280=	١		
		***************************************						Total add'l fee	\$		Total add'l fee	\$		
			Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed. A check in the amount of \$ to cover the filing fee is enclosed.											
			The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. I hereby petition under 37 CFR § 1 136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.											
		M												
						Respectful	Respectfully submitted,							
					4 March									
						Gregory M Registratio Agent for A	n No	. 48,492	,			-		
		P.O. BO	HOFER GILSON X 10395 GO, ILLINOIS 606 1-4200			, igonic ioi ,	·νρι	Sam						
	4	I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no EL 392680614US, with sufficient postage, in an envelope addressed to Assistant Commissioner for Patents, Washington, D C 20231, on 120 120 120 120 120 120 120 120 120 120												
	o * .	Date: 6	130/02	Signa	ture	vy								

rev. Dec.-00

OIP Edit of Deposit: 61/30/02

Our Case No. 10466/69

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Ashkenazi et al.

Examiner:

Unassigned

Serial No.:

09/902,903

Group Art Unit No.: 1645

Filing Date:

July 10, 2001

For:

SECRETED AND

TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE

SAME

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In reply to the attached Notice to File Corrected Application Papers (dated November 7, 2001), Applicant has enclosed one hundred and twenty-four (124) sheets of formal drawings. Please substitute the enclosed sheets of formal drawings for the one hundred and twenty-four (124) sheets of drawings originally filed with the application.

Respectfully submitted,

Dated: 01/30/0V

Gregory M. Zinkl, Ph.D. Registration No. 48,492

Agent for Applicant

BRINKS, HOFER, GILSON & LIONE

P.O. BOX 10395

CHICAGO, ILLINOIS 60610



JAN 3 0 2002

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/902,903

07/10/2001

Avi Ashkenazi

P1618P2C32

CONFIRMATION NO. 1524

FORMALITIES LETTER

OC000000007142208

Date Mailed: 11/30/2001

aul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov